Press Releases

BeiGene to Present at Upcoming Investor Conferences

March 4, 2019 at 7:00 AM EST

CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the company will present at two upcoming investor conferences:

The Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11th at 4:10 p.m. ET; and

The 2019 Barclays Global Healthcare Conference in Miami on Wednesday, March 13th at 3:20 p.m. ET.

Live webcasts can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ and archived replays will be available for 90 days following the event.

About BeiGeneBeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,200 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i

Site Navigation

Footer

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed six drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of February 27, 2019, the Company had a global team of over 2,200 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.